{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:22:16Z","timestamp":1770751336042,"version":"3.50.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15555-9","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T09:47:55Z","timestamp":1768384075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiple-day dexamethasone for controlling delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Akari","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6183-4939","authenticated-orcid":false,"given":"Toshinobu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudai","family":"Harimitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurino","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Ushio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimichi","family":"Koutake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"15555_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura CK, et al. 2023 Japan society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol. 2024;29:873\u201388. https:\/\/doi.org\/10.1007\/s10147-024-02535-x.","journal-title":"Int J Clin Oncol"},{"key":"15555_CR2","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:2782\u201397. https:\/\/doi.org\/10.1200\/JCO.20.01296.","journal-title":"J Clin Oncol"},{"key":"15555_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00520-023-08223-2","volume":"32","author":"I Olver","year":"2023","unstructured":"Olver I, Clark-Snow R, Ruhlmann CH, Garcia-Del-Barrio MA, Schwartzberg L, et al. 2023 updated MASCC\/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Support Care Cancer. 2023;32:37. https:\/\/doi.org\/10.1007\/s00520-023-08223-2.","journal-title":"Support Care Cancer"},{"key":"15555_CR4","unstructured":"NCCN. NCCN clinical practice guidelines in oncology. Antiemetics. Version 2. 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed Aug 11, 2025."},{"key":"15555_CR5","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s00520-011-1278-6","volume":"20","author":"T Hayashi","year":"2015","unstructured":"Hayashi T, Ikesue H, Esaki T, Fukazawa M, Abe M, Ohno S, et al. Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: A clinical and cost evaluation. Support Care Cancer. 2015;20:1805\u201310. https:\/\/doi.org\/10.1007\/s00520-011-1278-6.","journal-title":"Support Care Cancer"},{"key":"15555_CR6","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00520-017-3679-7","volume":"25","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Shimokawa M, Miyoshi T, Toriyama Y, Yokota C, Taniguchi J, et al. A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. Support Care Cancer. 2017;25:2707\u201314. https:\/\/doi.org\/10.1007\/s00520-017-3679-7.","journal-title":"Support Care Cancer"},{"key":"15555_CR7","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.2147\/CMAR.S176574","volume":"10","author":"T Hayashi","year":"2018","unstructured":"Hayashi T, Shimokawa M, Matsuo K, Miyoshi T, Toriyama Y, Yokota C, et al. Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: A prospective, observational, multicenter study. Cancer Manag Res. 2018;10:4249\u201355. https:\/\/doi.org\/10.2147\/CMAR.S176574.","journal-title":"Cancer Manag Res"},{"key":"15555_CR8","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472\u20138. https:\/\/doi.org\/10.1200\/JCO.2006.05.6382.","journal-title":"J Clin Oncol"},{"key":"15555_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41416-023-02493-7","volume":"130","author":"H Minatogawa","year":"2024","unstructured":"Minatogawa H, Izawa N, Shimomura K, Arioka H, Iihara H, Sugawara M, et al. Dexamethasone-sparing on days 2\u20134 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: A randomized phase III trial (SPARED Trial). Br J Cancer. 2024;130:224\u201332. https:\/\/doi.org\/10.1038\/s41416-023-02493-7.","journal-title":"Br J Cancer"},{"key":"15555_CR10","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","volume":"36","author":"Y Ito","year":"2018","unstructured":"Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M, et al. Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined Neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. J Clin Oncol. 2018;36:1000\u20136. https:\/\/doi.org\/10.1200\/JCO.2017.74.4375.","journal-title":"J Clin Oncol"},{"key":"15555_CR11","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1007\/s00520-021-06061-8","volume":"29","author":"T Hayashi","year":"2021","unstructured":"Hayashi T, Shimokawa M, Mizuki F, Matsuo K, Kawada K, Nakano T, et al. Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score\u2013matched analysis. Support Care Cancer. 2021;29:5029\u201335. https:\/\/doi.org\/10.1007\/s00520-021-06061-8.","journal-title":"Support Care Cancer"},{"key":"15555_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1634\/theoncologist.8-2-187","volume":"8","author":"FM Schnell","year":"2003","unstructured":"Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003;8:187\u201398. https:\/\/doi.org\/10.1634\/theoncologist.8-2-187.","journal-title":"Oncologist"},{"key":"15555_CR13","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1056\/NEJM200005253422102","volume":"342","author":"Italian Group for Antiemetic Research","year":"2000","unstructured":"Italian Group for Antiemetic Research. Dexamethasone alone or in combination with Ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med. 2000;342:1554\u20139. https:\/\/doi.org\/10.1056\/NEJM200005253422102.","journal-title":"N Engl J Med"},{"key":"15555_CR14","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482\u201394. https:\/\/doi.org\/10.1056\/NEJMra0706547.","journal-title":"N Engl J Med"},{"key":"15555_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199501053320101","volume":"332","author":"Italian Group for Antiemetic Research","year":"1995","unstructured":"Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med. 1995;332:1\u20135. https:\/\/doi.org\/10.1056\/NEJM199501053320101.","journal-title":"N Engl J Med"},{"key":"15555_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 2006;94:1011\u20135. https:\/\/doi.org\/10.1038\/sj.bjc.6603048.","journal-title":"Br J Cancer"},{"key":"15555_CR17","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1634\/theoncologist.2016-0308","volume":"22","author":"M Nakamura","year":"2017","unstructured":"Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K, et al. A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in Gastrointestinal cancer (ESPRESSO-01). Oncologist. 2017;22:592\u2013600. https:\/\/doi.org\/10.1634\/theoncologist.2016-0308.","journal-title":"Oncologist"},{"key":"15555_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fphar.2017.00019","volume":"8","author":"BL Rapoport","year":"2017","unstructured":"Rapoport BL. Delayed chemotherapy-induced nausea and vomiting: Pathogenesis, incidence, and current management. Front Pharmacol. 2017;8:19. https:\/\/doi.org\/10.3389\/fphar.2017.00019.","journal-title":"Front Pharmacol"},{"key":"15555_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","volume":"20","author":"TL Ng","year":"2015","unstructured":"Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist. 2015;20:576\u201383. https:\/\/doi.org\/10.1634\/theoncologist.2014-0438.","journal-title":"Oncologist"},{"key":"15555_CR20","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.2147\/OTT.S158570","volume":"11","author":"RM Navari","year":"2018","unstructured":"Navari RM, Schwartzberg LS. Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. Onco Targets Ther. 2018;11:6459\u201378. https:\/\/doi.org\/10.2147\/OTT.S158570.","journal-title":"Onco Targets Ther"},{"key":"15555_CR21","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1007\/s00520-012-1527-3","volume":"20","author":"PJ Hesketh","year":"2012","unstructured":"Hesketh PJ, Morrow G, Komorowski AW, Ahmed R, Cox D. Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC). Support Care Cancer. 2012;20:2633\u20137. https:\/\/doi.org\/10.1007\/s00520-012-1527-3.","journal-title":"Support Care Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15555-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15555-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15555-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:00:51Z","timestamp":1770721251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15555-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15555"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15555-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Independent Ethics Committee of National Hospital Organization Kyushu Cancer Center (2013-79) and conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects. Written informed consent was obtained from the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}